Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...
TIXiMED, Inc. ( a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today announced the initiation of the Phase 1b Multiple Ascending ...
Hormonal changes throughout a woman’s life influence insulin needs, glucose regulation, and cardiovascular risk, highlighting ...
Spero Therapeutics gets a Buy on the immunology pivot, FDA-approved Utebzi, and $105M royalty deal funding SP001. Learn more ...
This infographic explores the key multiomics fields, their integration across research applications, and real-world case ...
New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients misclassified — and the clinical consequences are preventable. Our modern ...
Clinical trial evidence reviewed by an independent NICE committee shows that teplizumab can delay the onset of symptomatic type 1 diabetes by an average of nearly 3 years. Teplizumab is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results